---
title: "ImmuneOnco clarifies subsidiary capital increase as employee incentive scheme via ESOP platform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294512249.md"
description: "ImmuneOnco clarified that a subsidiary capital increase serves as an employee incentive via an ESOP platform, targeting senior management and core technical staff. The unit aims to raise external private funding for non-oncology R&D diversification. ImmuneOnco defended par-value subscriptions as standard practice, citing the target's net liabilities. Control of the ESOP platform is held by Jiaxing Hanlan (69.92%), Dr. Tian (21.48%), and Dr. Zheng (8.6%)."
datetime: "2026-07-31T12:18:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294512249.md)
  - [en](https://longbridge.com/en/news/294512249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294512249.md)
generator: "portal-rs"
---

# ImmuneOnco clarifies subsidiary capital increase as employee incentive scheme via ESOP platform

-   ImmuneOnco issued a supplemental clarification on its June 18, 2026 deemed disposal tied to a subsidiary capital increase. \* The unit was set up to raise external private funding for non-oncology R&D, aiming to diversify beyond the group’s core oncology programs. \* The capital increase was framed as an employee incentive via an ESOP platform, with participants expected to include senior management and core technical staff. \* It defended par-value subscriptions as standard for ESOPs, citing the target’s net liabilities as of Dec. 31, 2025. \* The ESOP platform’s control structure was updated: Jiaxing Hanlan holds about 69.92%, Dr. Tian 21.48%, Dr. Zheng 8.6%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12264946), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01541.HK](https://longbridge.com/en/quote/01541.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [ImmuneOnco doses first patient in Phase II trial of IMM2510-IMM27M combo for first-line advanced liver cancer](https://longbridge.com/en/news/297193348.md)
- [ImmuneOnco says first PAH patient dosed in Phase Ib/IIa trial of IMC-003](https://longbridge.com/en/news/296898622.md)
- [Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial](https://longbridge.com/en/news/298410878.md)
- [Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting | INTI Stock News](https://longbridge.com/en/news/298367952.md)
- [Opus Genetics reports positive Phase 1/2 low-dose Cohort 1 data for OPGx-BEST1 gene therapy in BEST1 retinal disease](https://longbridge.com/en/news/298445913.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**